ENTX 2018 - 06 - 29

Entera Bio Ltd.

ENTX | $2.21 -0.45% 19K

(0.0% 1d) (42.3% 1m) (217.1% 1y) (0.0% 2d) (8.3% 3d) (-0.9% 7d) (-32.99% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 78,413,764
http://www.enterabio.com
Sec Filling | Patents | 24 employees

(IL) Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. It develops an oral formulation of parathyroid hormone. The company was founded on June 1, 2010 and is headquartered in Jerusalem, Israel.

hormone israel osteoporosis eb613 bone

add to watch list Paper trade email alert is off

Press-releases

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| 13.55% | O: 2.3% H: 1.25% C: -2.5%
eb613 publication research bone trial

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
Published: 2024-03-26 (Crawled : 12:30) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| 42.31% | O: 12.18% H: 0.0% C: -11.43%
eb613 fda expected osteoporosis key milestone

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
OPK | $1.225 -2.0% 3.5M

Health Technology

| 43.63% | O: 1.08% H: 5.01% C: 1.17%
ENTX | $2.21 -0.45% 19K

Health Technology

| 57.42% | O: 0.69% H: 8.45% C: 7.04%
treatment

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
Published: 2024-03-08 (Crawled : 21:00) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| Email alert Add to watchlist
business year financial results

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| 54.17% | O: 3.47% H: 17.45% C: 15.44%
nasdaq

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-01-30 (Crawled : 13:30) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| 150.17% | O: -0.83% H: 0.28% C: -1.14%
conference life sciences

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| 238.98% | O: 0.78% H: 0.0% C: -2.29%
nasdaq extension

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
Published: 2023-12-26 (Crawled : 13:00) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| 241.54% | O: 3.08% H: 5.97% C: -2.58%

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
Published: 2023-11-29 (Crawled : 13:30) - globenewswire.com
ENTX | $2.21 -0.45% 19K

Health Technology

| 216.33% | O: 2.55% H: 1.42% C: -2.88%
eb613 osteoporosis treatment ongoing potential results study platform

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
OPK | $1.225 -2.0% 3.5M

Health Technology

| -2.34% | O: 2.34% H: 6.87% C: 6.11%
ENTX | $2.21 -0.45% 19K

Health Technology

| 217.14% | O: 0.0% H: 3.0% C: 2.86%
company financial potential

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001178913-24-001423	4	2024-04-23	2024-04-19	Buy	A	130000	130000
0001178913-24-001423	4	2024-04-23	2024-04-19	Buy	A	30151	86731
0001178913-24-000164	4	2024-01-16	2024-01-12	Buy	P	9500	35115